Table 4.
Reduced intensity conditioning
| Factor | n | Event | HR | HR low | HR upper | P |
|---|---|---|---|---|---|---|
| Relapse | ||||||
| Donor KIR haplotype | .026 * | |||||
| AA | 334 | 130 | 1 | |||
| BX | 730 | 240 | 0.77 | 0.62 | 0.97 | .026 |
| Cytogenetics | .0025 * | |||||
| Disease status | .0001 * | |||||
| Early | 837 | 277 | 1 | |||
| Intermediate | 218 | 87 | 1.34 | 1.05 | 1.72 | .019 |
| Advanced | 9 | 6 | 3.97 | 1.88 | 8.36 | .0003 |
| ATG/alemtuzumab | .021 | |||||
| No ATG/alemtuzumab | 617 | 207 | 1.00 | |||
| ATG alone | 404 | 155 | 1.18 | 0.88 | 1.56 | .28 |
| Alemtuzumab alone | 43 | 8 | 0.59 | 0.36 | 0.96 | .035 |
| HLA-DP mismatch | .54 | |||||
| Fully matched | 178 | 66 | 1.00 | |||
| Mismatch | 872 | 299 | 0.99 | 0.73 | 1.24 | .94 |
| Missing | 14 | 5 | 1.29 | 0.77 | 2.15 | .33 |
| Donor KIR centromeric regions | .051 * | |||||
| AA | 483 | 183 | 1.00 | |||
| AB | 483 | 155 | 0.77 | 0.61 | 0.98 | .035 |
| BB | 98 | 32 | 0.77 | 0.54 | 1.09 | .14 |
| Cytogenetics | .0024 * | |||||
| Disease status | <.0001 * | |||||
| Early | 837 | 277 | 1.00 | |||
| Intermediate | 218 | 87 | 1.37 | 1.06 | 1.75 | .014 |
| Advanced | 9 | 6 | 4.08 | 1.95 | 8.51 | .0002 |
| ATG/alemtuzumab | .029 | |||||
| No ATG/alemtuzumab | 617 | 207 | 1.00 | |||
| ATG alone | 404 | 155 | 1.16 | 0.87 | 1.54 | .32 |
| Alemtuzumab alone | 43 | 8 | 0.59 | 0.36 | 0.98 | .043 |
| HLA-DP mismatch | .49 | |||||
| Fully matched | 178 | 66 | 1.00 | |||
| Mismatch | 872 | 299 | 0.98 | 0.72 | 1.33 | .89 |
| Missing | 14 | 5 | 1.30 | 0.78 | 2.15 | .31 |
| DFS | ||||||
| KIR B haplotype | .038 | |||||
| AA | 334 | 214 | 1.00 | |||
| BX | 728 | 423 | 0.84 | 0.72 | 0.99 | .038 |
| HLA matched alleles | .042 | |||||
| 7/8 | 145 | 106 | 1.00 | |||
| 8/8 | 917 | 531 | 0.78 | 0.61 | 0.99 | .042 |
| Cytogenetics | .0012 | |||||
| Donor age | .053 | |||||
| Disease status | .022 | |||||
| Early | 836 | 487 | 1.00 | |||
| Intermediate | 218 | 142 | 1.18 | 0.98 | 1.43 | .085 |
| Advanced | 8 | 8 | 3.01 | 1.22 | 7.40 | .017 |
| Recipient age, y | .20 | |||||
| 20-29 | 23 | 13 | 1.00 | |||
| 30-39 | 29 | 15 | 0.69 | 0.33 | 1.44 | .32 |
| 40-49 | 57 | 33 | 0.98 | 0.52 | 1.83 | .95 |
| 50-59 | 198 | 116 | 0.97 | 0.58 | 1.64 | .92 |
| ≥60 | 755 | 460 | 1.07 | 0.64 | 1.80 | .80 |
| Recipient CMV status | .035 | |||||
| ATG/alemtuzumab | .31 | |||||
| No ATG/alemtuzumab | 615 | 363 | 1.00 | |||
| ATG alone | 404 | 245 | 1.04 | 0.85 | 1.27 | .71 |
| Alemtuzumab alone | 43 | 29 | 1.22 | 0.95 | 1.58 | .12 |
| HLA-DP mismatch | .10 | |||||
| Fully matched | 178 | 109 | 1.00 | |||
| Mismatch | 871 | 519 | 1.06 | 0.84 | 1.34 | .64 |
| Missing | 13 | 9 | 1.69 | 1.10 | 2.60 | .017 |
| Donor KIR centromeric regions | .034 | |||||
| AA | 482 | 308 | 1.00 | |||
| AB | 483 | 278 | 0.82 | 0.70 | 0.96 | .016 |
| BB | 97 | 51 | 0.76 | 0.56 | 1.02 | .069 |
| HLA matched alleles | .057 | |||||
| 7/8 | 145 | 106 | 1.00 | |||
| 8/8 | 917 | 531 | 0.79 | 0.61 | 1.01 | .057 |
| Cytogenetics | .0009 | |||||
| Donor age | .054 | |||||
| Disease status | .013 | |||||
| Early | 836 | 487 | 1.00 | |||
| Intermediate | 218 | 142 | 1.20 | 0.99 | 1.45 | .064 |
| Advanced | 8 | 8 | 3.06 | 1.28 | 7.31 | .012 |
| Recipient age, y | ||||||
| 20-29 | 23 | 13 | 1.00 | |||
| 30-39 | 29 | 15 | 0.68 | 0.32 | 1.44 | .31 |
| 40-49 | 57 | 33 | 0.96 | 0.52 | 1.80 | .91 |
| 50-59 | 198 | 116 | 0.96 | 0.57 | 1.62 | .88 |
| ≥60 | 755 | 460 | 1.05 | 0.62 | 1.77 | .85 |
| Recipient CMV status | .052 | |||||
| ATG/alemtuzumab | .25 | |||||
| No ATG/alemtuzumab | 615 | 363 | 1.00 | |||
| ATG alone | 404 | 245 | 1.03 | 0.84 | 1.26 | .79 |
| Alemtuzumab alone | 43 | 29 | 1.24 | 0.96 | 1.60 | .10 |
| HLA-DP mismatch | .036 | |||||
| Fully matched | 178 | 109 | 1.00 | |||
| Mismatch | 871 | 519 | 1.05 | 0.83 | 1.33 | .66 |
| Missing | 13 | 9 | 1.71 | 1.13 | 2.58 | .011 |
Stratified variables: Karnofsky performance score. Poor risk cytogenetics significantly associated with risks of relapse in RIC and MAC adjusted for other covariates. Bolded P values are independently significant P < .05.
*
Adjusted multivariate analysis for the end points shown stratified as indicated.